Floatz logo

Epirubicin

High Grade Ovarian Serous Adenocarcinoma

Roswell Park Cancer InstitutePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the High Grade Ovarian Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Roswell Park Cancer Institute
Phase 2BB
Nivolumab
pharmaand GmbH
Phase 2B
Niraparib
Sunnybrook Health Sciences Centre
Phase 2B
Ipilimumab
TCR2 Therapeutics
Phase 1/2CCC
Copanlisib
National Cancer Institute (NCI)
Phase 2CCC

View all 18 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →